Non-HDL Cholesterol As a Metric of Good Quality of Care: Opportunities and Challenges

Overview

Journal Tex Heart Inst J

Specialty Cardiology & Vascular Diseases

Date 2011 Apr 16

PMID 21494527

Citations 37

Authors

Salim S Virani

Affiliations

Soon will be listed here.

Citing Articles

Obesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study.

Nonterah E, Agongo G, Crowther N, Mohamed S, Micklesfield L, Boua P PLoS One. 2025; 20(1):e0316527.

PMID: 39883633 PMC: 11781721. DOI: 10.1371/journal.pone.0316527.

Glucose and Lipid Metabolism Disorders in Adults with Spinal Muscular Atrophy Type 3.

Miletic M, Stevic Z, Vujovic S, Rakocevic J, Tomic A, Tancic Gajic M Diagnostics (Basel). 2024; 14(18).

PMID: 39335757 PMC: 11431033. DOI: 10.3390/diagnostics14182078.

The performance of lipid profiles and ratios as a predictor of arterial stiffness measured by brachial-ankle pulse wave velocity in type 2 diabetic patients.

Soelistijo S, Adiwinoto R, Pranoto A, Ardiany D F1000Res. 2024; 11:1582.

PMID: 39221025 PMC: 11364966. DOI: 10.12688/f1000research.128627.2.

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond.

Safarova M, Bimal T, Soffer D, Hirsh B, Shapiro M, Mintz G Am J Prev Cardiol. 2024; 19:100701.

PMID: 39070027 PMC: 11278114. DOI: 10.1016/j.ajpc.2024.100701.

Physical activity in metabolic syndrome.

Chomiuk T, Niezgoda N, Mamcarz A, Sliz D Front Physiol. 2024; 15:1365761.

PMID: 38440349 PMC: 10910017. DOI: 10.3389/fphys.2024.1365761.

References

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

Brunzell J, Davidson M, Furberg C, Goldberg R, Howard B, Stein J . Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008; 51(15):1512-24. DOI: 10.1016/j.jacc.2008.02.034. View

Virani S, Woodard L, Landrum C, Pietz K, Wang D, Ballantyne C . Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011; 161(6):1140-6. DOI: 10.1016/j.ahj.2011.03.023. View

Davidson M, Maki K, Pearson T, Pasternak R, Deedwania P, McKenney J . Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005; 96(4):556-63. DOI: 10.1016/j.amjcard.2005.04.019. View

Kastelein J, van der Steeg W, Holme I, Gaffney M, Cater N, Barter P . Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008; 117(23):3002-9. DOI: 10.1161/CIRCULATIONAHA.107.713438. View

Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-504. DOI: 10.1056/NEJMoa040583. View

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

Sattar N, Williams K, Sniderman A, DAgostino Jr R, Haffner S . Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004; 110(17):2687-93. DOI: 10.1161/01.CIR.0000145660.60487.94. View

FRICK M, ELO O, Haapa K, Heinonen O, Heinsalmi P, Helo P . Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317(20):1237-45. DOI: 10.1056/NEJM198711123172001. View

10.

Ballantyne C, Andrews T, Hsia J, Kramer J, Shear C . Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001; 88(3):265-9. DOI: 10.1016/s0002-9149(01)01638-1. View

11.

Blaha M, Blumenthal R, Brinton E, Jacobson T . The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2011; 2(4):267-73. DOI: 10.1016/j.jacl.2008.06.013. View